Thumbnail Image
Publication

The High Price of Aduhelm’s Approval: An Investigation into FDA’s Atypical Review Process and Biogen’s Aggressive Launch Plans

House Committee on Energy and Commerce
Abstract
The House Committee on Energy and Commerce and House Committee on Oversight and Reform issued a House Joint Staff Report on the Alzheimer's disease drug, Aduhelm.
Date
2022-12-29
Document Type
House Joint Staff Report
Serial Number
Document Length
46 pages
Congress
117
Show all metadata
Files
Thumbnail Image
2022-12-29_R-High_Price_Approval-117C.pdf
Adobe PDF, 1.8 MB
URI
https://hdl.handle.net/20.500.14300/2744
Relation
DOI
Keywords
Staff Reports, House
PAP Major Code
3: Health
PAP Minor Code
321: Regulation of Drug Industry, Medical Devices, and Clinical Labs
Related Hearings
Press Releases and Contextual Information
Collections
House Committee on Energy and Commerce